Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 16 Source: CRO
- €103 million turnover
-
€85.7 million
profit - 111 employees
-
31st Dec 15 Source: CRO
- €89.4 million turnover
-
€74.3 million
profit - 99 employees
- 4 more years available »
Ranking
By Turnover
(€103 million)- 457th in Top Companies
- 49th in Health
- 47th in Pharma
- 67th in Manufacturing
By Employees
(111)- 690th in Top Companies
- 82nd in Health
- 63rd in Pharma
- 106th in Manufacturing
- 111
- €103 million
Employees
- James Byrne General Manager
Latest News
- 7:21am GAN raises £7.5m to target US internet sports betting
- 7:06am The race for the ECB presidency is heating up
- 6:30am Potential for 25,000 new pharma jobs, US-China trade deal, and Titanic tourism
- 6:22am Profits at Ryanair soar by 10% to €1.5bn in 2018
- 5:48am Gilead Sciences launches €9.5m unit at Cork plant